Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alaunos Therapeutics, Inc. (TCRT) filings document an early-stage biotechnology issuer with a developing small-molecule program, a legacy TCR-T oncology platform and a public-company capital structure. Form 8-K reports cover ALN1003 preclinical disclosures, material agreements, settlement matters, Nasdaq continued-listing notices, governance changes, director and officer transitions, and modifications to stockholder rights.
Registration statements, annual meeting reports and periodic-report references describe securities offerings, authorized common stock, stockholder voting results, operating and financial results, risk factors, and stockholders' equity used in Nasdaq compliance determinations.
Alaunos Therapeutics, Inc. (TCRT) reported that on September 16, 2026 its Board of Directors approved and adopted Second Amended and Restated By-Laws, effective immediately, fully replacing the by-laws adopted January 8, 2026.
The principal change revises the stockholder meeting quorum requirement in Article 2, Section 2.8. Previously, a quorum required the presence in person or by proxy of the holders of a majority in voting power of all outstanding shares entitled to vote. Under the new by-laws, a quorum is reached when holders of one-third (1/3) in voting power of outstanding shares entitled to vote are present in person or by proxy. Provisions governing adjournment without a quorum are otherwise unchanged, the quorum requirement for Board and committee meetings remains a majority, and other modifications are described as conforming, clarifying, and non-substantive. The full text of the Second Amended and Restated By-Laws is included as Exhibit 3.1.
Alaunos Therapeutics, Inc. reports that it remains a preclinical-stage obesity and metabolic disorders company with no product revenue and continued losses. For the six months ended June 30, 2026, it recorded a net loss of $1.96 million and had an accumulated deficit of $926.6 million since inception. Cash and cash equivalents were only $0.12 million, with total assets of $1.52 million and stockholders’ equity of $0.65 million, resulting in a working capital deficit.
Management states that current capital will fund operations only into the third quarter of 2026 and concludes there is substantial doubt about the company’s ability to continue as a going concern without substantial additional financing. The company has an equity purchase agreement that yielded just $70,000 of net proceeds in the first half of 2026 and has no committed additional capital. Alaunos also received a Nasdaq stockholders’ equity deficiency notice, as equity is below the $2.5 million continued listing requirement, and it highlights possible future exposure to a proposed $5.0 million Market Value of Listed Securities standard.
Operationally, Alaunos is winding down legacy TCR-T programs and focusing on lead small-molecule candidate ALN1003 for obesity and metabolic syndrome, reporting encouraging non-GLP diet-induced obesity mouse data across weight loss, liver markers, and insulin-resistance-related biomarkers. However, these findings are preclinical, non-GLP, and subject to substantial development and financing risks before any clinical testing.
Alaunos Therapeutics, Inc. reported that CEO Holger Weis received a grant of common stock as part of his compensation. On 2026-08-06, he acquired 4,363 shares of common stock at a value of $2.01 per share, issued in lieu of net salary. Following this stock issuance, Weis directly owns 25,483 shares of Alaunos Therapeutics common stock.
Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. reported that director Michael Allen Jerman received a grant of 8,138 shares of common stock on 2026-07-23, valued at $1.92 per share. The shares were issued in lieu of board fees and increase his direct holdings to 23,759 shares.
Alaunos Therapeutics, Inc. CEO Holger Weis received a grant of 4,568 shares of common stock on 2026-07-23 at $1.92 per share, issued in lieu of net salary. After this compensation-related acquisition, he directly holds 21,120 common shares.
Robert W. Postma, a director of Alaunos Therapeutics, Inc., reported the acquisition of 8,463 shares of common stock on 23 July 2026 at $1.92 per share, described as shares issued in lieu of board fees. Following this grant, he holds 58,609 shares directly and additional indirect holdings of 24 shares through his spouse's IRA and 62,416 shares through WaterMill Asset Management Corp.
Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. director Jaime Vieser reported an equity compensation grant of 8,789 shares of common stock on 2026-07-23, valued at $1.92 per share and issued in lieu of board fees. Following this award, he holds 47,642 shares directly. The report also lists indirect holdings of 2,100 shares held by his children and 13,503 shares held by Brushwood LLC, where he serves as Manager.
Alaunos Therapeutics Chief Executive Officer Holger Weis received a stock grant as compensation. On June 30, 2026, he acquired 3,880 shares of Alaunos common stock at $2.26 per share in a grant issued in lieu of net salary. Following this award, he directly holds 16,552 common shares, and no derivative positions are reported in this filing.
Alaunos Therapeutics filed a current report describing new preclinical data for ALN1003, its investigational oral, non-hormonal, non-incretin metabolic candidate, from a 48-day diet-induced obesity mouse study. After adjusting for body fat percentage in an ANCOVA, ALN1003-treated animals showed significantly lower liver weight than controls, with p=0.000005 and confirmation using heteroscedasticity-robust HC3 standard errors.
The company notes this liver-weight signal is directionally consistent with earlier findings of lower liver injury enzymes, lower mean NAFLD Activity Scores, lower HOMA-IR, and favorable adipose endocrine biomarkers, but emphasizes the data are from non-GLP mouse studies that may not translate to humans. As of March 31, 2026, Alaunos reported cash and cash equivalents of about $0.354 million and plans to seek additional financing to continue operations and advance its obesity and metabolic disorders program.
Alaunos Therapeutics Chief Executive Officer Holger Weis reported a stock-based compensation transaction. On June 12, 2026, he acquired 7,761 shares of Alaunos common stock at $2.26 per share as a grant categorized as a "grant, award, or other acquisition." A footnote explains these shares were issued in lieu of net salary, indicating they are compensation rather than an open‑market purchase. Following this award, Weis directly holds 12,672 common shares of Alaunos Therapeutics.